Changes in biological markers, particularly hormone receptors, due to pre-operative chemotherapy (epirubicin/docetaxel) in operable breast cancer

by Rumiko Tashima, Reiki Nishimura
Published 2011-12-01

Clinical Significance of CK19 Negative Breast Cancer

by Nobuyuki Arima, Tomofumi Osako, Yasuo Toyozumi, Yasuyuki Nishiyama, Rumiko Tashima, Yasuhiro Okumura, Reiki Nishimura, Mamiko Fujisue
Published 2012-12-01

Evaluation of an Optimal Cut-Off Point for the Ki-67 Index as a Prognostic Factor in Primary Breast Cancer: A Retrospective Study.

by Rumiko Tashima, Reiki Nishimura, Tomofumi Osako, Yasuyuki Nishiyama, Yasuhiro Okumura, Masahiro Nakano, Mamiko Fujisue, Yasuo Toyozumi, Nobuyuki Arima
Published 2015-01-01

Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study

by Masato Takahashi, Norikazu Masuda, Reiki Nishimura, Kenichi Inoue, Shinji Ohno, Hiroji Iwata, Satoshi Hashigaki, Yasuaki Muramatsu, Yoshiko Umeyama, Masakazu Toi
Published 2020-07-01

BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer.

by Hitomi Mori, Makoto Kubo, Reiki Nishimura, Tomofumi Osako, Nobuyuki Arima, Yasuhiro Okumura, Masayuki Okido, Mai Yamada, Masaya Kai, Junji Kishimoto, Tetsuyuki Miyazaki, Yoshinao Oda, Takao Otsuka, Masafumi Nakamura
Published 2016-01-01